-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

4633 Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Updated Follow-up of Transcend CLL 004

Program: Oral and Poster Abstracts
Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III
Hematology Disease Topics & Pathways:
Research, Clinical trials, Lymphoid Leukemias, Adult, CLL, Lymphomas, Non-Hodgkin lymphoma, Clinical Research, B Cell lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Study Population, Human
Monday, December 9, 2024, 6:00 PM-8:00 PM

Tanya Siddiqi, MD, MBBS1*, Jordan Gauthier, MD, MSc2*, Saad S. Kenderian, MD3, Danielle M. Brander, MD4, Kathleen Dorritie, MD5, Jacob D. Soumerai, MD6, Peter A. Riedell, MD7, Nirav N. Shah, MD8, Rajneesh Nath, MD9, Charalambos Andreadis, MD, MS10*, Daniel A. Ermann, MD11, Shuo Ma, MD, PhD12, Tatyana Feldman, MD13*, Scott R. Solomon, MD14, Stephen J. Schuster, MD15, Sherilyn A. Tuazon, MD16*, Serena K. Perna, MD17*, San-San Ou, MS16*, Neha Rane, MD17*, Eniko Papp, PhD16*, Yizhe Chen, PhD17* and William G. Wierda18

1City of Hope National Medical Center, Duarte, CA
2Fred Hutchinson Cancer Center, Seattle, WA
3Mayo Clinic, Rochester, MN
4Duke Cancer Institute, Durham, NC
5UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA
6Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA
7David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL
8Medical College of Wisconsin, Milwaukee, WI
9Banner MD Anderson Cancer Center, Scottsdale, AZ
10University of California, San Francisco, San Francisco, CA
11Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
12Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Northwestern University, Chicago, IL
13John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ
14Northside Hospital Cancer Institute, Atlanta, GA
15Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
16Bristol Myers Squibb, Seattle, WA
17Bristol Myers Squibb, Princeton, NJ
18The University of Texas MD Anderson Cancer Center, Houston, TX

Background: The primary analysis of the phase 1/2, single-arm, multicenter TRANSCEND CLL 004 (NCT03331198) study with a median follow-up of 21.1 mo showed that a single administration of liso-cel achieved rapid, deep, and durable responses and a manageable safety profile in pts with heavily pretreated, high-risk R/R CLL/SLL, including those with progression on a previous Bruton tyrosine kinase inhibitor (BTKi) and venetoclax failure (primary efficacy analysis set [PEAS]; Siddiqi T, et al. Lancet 2023). With 5 mo of additional follow-up (median of 23.5 mo), liso-cel continued to demonstrate durable CR/CR with incomplete marrow recovery (CRi) and high undetectable MRD (uMRD; 10−4 by next-generation sequencing) rates with no new safety signals. Median duration of response (DOR) was 35.3 mo (95% CI, 12.4–not reached [NR]), and median OS was 30.3 mo (95% CI, 15.0–NR) (Siddiqi T, et al. Blood 2023). Here, we report updated results from TRANSCEND CLL 004 with 16 mo of additional follow-up since primary analysis and a median on-study follow-up of 23.8 mo (range, 0.4–59.6).

Methods: Pts must have received ≥ 2 prior lines of therapy (LOTs), including a BTKi (full population). Eligible pts received liso-cel at a target dose of either 50 × 106 (dose level [DL] 1) or 100 × 106 (DL2) CAR+ T cells after lymphodepleting chemotherapy. The primary endpoint was CR/CRi per independent review committee in the PEAS at DL2. Key secondary endpoints were ORR and blood uMRD rate. All pts who received liso-cel and completed or discontinued early from the study were asked to enroll in a separate long-term follow-up (LTFU) study (NCT03435796) assessing safety and OS for up to 15 y after liso-cel.

Results: As of the data cutoff (01/12/2024), 118 of 137 leukapheresed pts received liso-cel (safety set), 97 (DL1, n = 9; DL2, n = 88) were efficacy evaluable, and 54 (DL1, n = 4; DL2, n = 50) were in the PEAS. A total of 22 pts were ongoing in TRANSCEND CLL 004, and 19 of 60 eligible pts enrolled to the LTFU study. In the safety set, pts had a median age of 65 y (range, 49–82), and 83% had high-risk cytogenetic markers (del[17p], 42%; TP53 mutation, 47%; unmutated immunoglobulin heavy-chain variable gene, 47%). Median prior LOTs was 5 (range, 2–14); 86% of pts had prior chemoimmunotherapy.

In the PEAS at DL2, CR/CRi rate remained at 20%, ORR at 44%, blood uMRD rate at 64%, and marrow uMRD rate at 60%. Median DOR was NR (95% CI, 12.4–NR), with a median follow-up of 31.7 mo (95% CI, 21.3–35.5). Estimated 36-mo DOR rate was 61% (95% CI, 30–81). Median (95% CI) DOR was NR in pts with CR/CRi. Median (95% CI) PFS was 11.9 mo (5.7–26.2) overall, 26.2 mo (11.9–NR) in pts with blood uMRD, and 2.8 mo (0.8–3.2) in pts with detectable blood MRD. Median OS, including 19 pts in the LTFU, was 43.2 mo (95% CI, 14.5–NR). Efficacy outcomes were similar in the full population at DL2.

A subgroup of 23 pts who had only prior BTKi exposure and were venetoclax naïve was less heavily pretreated, with a median of 3 prior LOTs (range, 2–11); all pts had prior chemoimmunotherapy. In the efficacy-evaluable pts of this subgroup at DL2 (n = 18), the CR/CRi rate was 22%; ORR was 61%; and median (95% CI) DOR was NR (17.1–NR), PFS was NR (18.0–NR), and OS was 52.2 mo (26.9–NR).

In the safety set, rates of any-grade/grade ≥ 3 cytokine release syndrome (85%/8%), any-grade/grade ≥ 3 neurological events (45%/19%), prolonged cytopenia (grade ≥ 3 at Day 30 after liso-cel infusion [54%]), grade ≥ 3 infections (18%), and second primary malignancy (9%) remained the same as previously reported (Siddiqi T, et al. Blood 2023); most pts with prolonged cytopenia had resolution to grade ≤ 2 by Month 3. Forty-six (34%) of 137 leukapheresed pts died after CAR T cell infusion, including 1 additional pt since the previous report with an unknown cause of death at ~14.5 mo after infusion. Persistence of the liso-cel transgene was detected up to 48 months after liso-cel infusion (2/5 evaluable pts at DL2 at Month 48).

Conclusions: In this updated follow-up, liso-cel continued to demonstrate durable responses with an extended median OS of 43.2 mo in pts with R/R CLL/SLL. The safety results were similar to those previously reported with no new safety signals. These data confirm the sustained clinical benefit and favorable benefit-to-risk profile of a single treatment of liso-cel in pts with R/R CLL/SLL.

Disclosures: Siddiqi: BMS: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Beigene: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees; Gilead: Other: Ad board; Astra Zeneca: Speakers Bureau. Gauthier: Sobi, Legend Biotech, Janssen, Kite Pharma, MorphoSys: Honoraria; Sobi, Juno Therapeutics (a BMS company), Celgene (a BMS company), Angiocrine Bioscience, Faron Pharmaceuticals, CARGO therapeutics: Research Funding; Century Therapeutics: Other: Independent Data Review Committee. Kenderian: Novartis, Kite/Gilead, Juno/BMS, Capstan, Humanigen, Carisma: Membership on an entity's Board of Directors or advisory committees; Kite/Gilead, Novartis, Carisma, Juno/BMS, Humanigen, Luminary: Consultancy; Novartis, Humanigen, MustangBio,: Patents & Royalties; Novartis, Kite/Gilead, Juno/BMS, Lentigen, Humanigen, Morphosys, Tolero, LeahLabs, InCyte, Viracta: Research Funding. Brander: BeiGene: Consultancy, Other: site PI clinical trial (grant paid to institution); Catapult: Other: site PI clinical trial (grant paid to institution); DTRM: Other: site PI clinical trial (grant paid to institution); Genentech: Consultancy, Other: site PI clinical trial (grant paid to institution); Juno/Celegene/BMS: Other: site PI clinical trial (grant paid to institution); NeWave: Other: site PI clinical trial (grant paid to institution); Nurix: Other: site PI clinical trial (grant paid to institution); Pharmacyclics: Consultancy, Other: site PI clinical trial (grant paid to institution); TG therapeutics: Other: site PI clinical trial (grant paid to institution); BMS: Other; AstraZeneca/Acereta: Other: site PI clinical trial (grant paid to institution); ArQule/Merck: Other: site PI clinical trial (grant paid to institution); AbbVie: Consultancy, Other: site PI clinical trial (grant paid to institution). Dorritie: Janssen: Honoraria, Research Funding; BMS: Honoraria, Research Funding; Genmab: Research Funding; Kite-Gilead: Research Funding; Hoffman La-Roche: Research Funding. Soumerai: Bristol Myers Squibb: Consultancy; Roche/Genentech: Consultancy, Research Funding; AstraZeneca: Consultancy, Honoraria, Research Funding; GlaxoSmithKline: Research Funding; Beigene: Consultancy, Research Funding; Moderna: Research Funding; Takeda: Research Funding; TG Therapeutics: Research Funding; BostonGene: Research Funding; Adaptive Biotechnologies: Research Funding; LOXO@Lilly: Consultancy. Riedell: Genmab: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Nektar Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees; BeiGene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Intellia Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees; Cellectis: Research Funding; Sana Biotechnology: Consultancy, Membership on an entity's Board of Directors or advisory committees; ADC Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Fate Therapeutics: Research Funding; Pharmacyclics: Consultancy, Membership on an entity's Board of Directors or advisory committees; Tessa Therapeutics: Research Funding; Cargo Therapeutics: Research Funding; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Genentech/Roche: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Kite/Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; CRISPR Therapeutics: Research Funding; Calibr: Research Funding; CVS Caremark: Consultancy, Membership on an entity's Board of Directors or advisory committees; Xencor: Research Funding; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Adaptive Biotechnologies: Honoraria. Shah: Miltenyi Biomedicine, Lilly Oncology: Research Funding; Gilead-Kite, BMS-Juno, Miltenyi, Lilly Onclogy, Novartis, Seattle Genetics, Janssen, Abbvie, Cargo, Beigene, Galapagos, AstraZeneca: Consultancy, Honoraria; Tundra Therapeutics: Current holder of stock options in a privately-held company. Nath: Incyte: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Daiichi Sankyo: Consultancy, Honoraria; Bristol Myers Squib: Consultancy, Honoraria; Autolus: Consultancy, Honoraria; Allogene: Consultancy, Honoraria; ADC Therapeutics: Consultancy, Honoraria; Actinium: Membership on an entity's Board of Directors or advisory committees. Andreadis: Novartis: Research Funding; Merck: Research Funding; Astra Zeneca: Consultancy; Gilead/Kite: Consultancy; Genmab: Research Funding; Abbvie: Consultancy; BMS: Consultancy; Seattle Genetics: Consultancy; Roche: Research Funding. Ermann: AstraZeneca: Speakers Bureau; Beigene, ADC therapeutics: Consultancy. Ma: Juno: Research Funding; Janssen: Consultancy; Lilly: Research Funding, Speakers Bureau; BeiGene: Consultancy, Research Funding, Speakers Bureau; AstraZeneca: Consultancy, Research Funding, Speakers Bureau; AbbVie: Consultancy, Honoraria, Research Funding. Feldman: Seagen: Consultancy, Speakers Bureau; AbbVie, AstraZeneca, Epizyme, Genmab, Gilead/Kite, Karyopharm, Takeda: Consultancy. Schuster: AbbVie: Consultancy; Pharmacyclics: Consultancy, Research Funding; Nordic Nanovector: Honoraria, Membership on an entity's Board of Directors or advisory committees; Kite Pharmaceuticals: Consultancy; Janssen: Consultancy, Honoraria, Research Funding; Gilead: Research Funding; Celgene/Juno Therapeutics: Consultancy, Honoraria, Research Funding; Genentech/Roche: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; viTToria biotherapeutics: Consultancy; AstraZeneca: Consultancy, Honoraria; Caribou Biosciences: Consultancy, Membership on an entity's Board of Directors or advisory committees; BioNTech: Consultancy; BeiGene: Consultancy, Honoraria; Genmab: Consultancy; Legend Biotech: Consultancy, Honoraria; Merck: Research Funding; Acerta: Consultancy. Tuazon: Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company. Perna: Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company. Ou: Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company. Rane: Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company. Papp: Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company. Chen: Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company. Wierda: BMS: Research Funding; Nurix Therapeutics: Research Funding; Kite: Research Funding; Pharmacyclics LLC, an AbbVie Company: Research Funding; Cyclacel Pharmaceuticals Inc: Research Funding; Loxo Oncology: Research Funding; Oncternal Therapeutics: Research Funding; AbbVie: Research Funding; Janssen: Research Funding; Eli Lilly: Research Funding; Oncternal Therapeutics: Research Funding; AstraZeneca: Research Funding; Accutar Biotechnology: Research Funding; GSK: Research Funding; Gilead Sciences: Research Funding; Genentech, Inc.: Research Funding; Numab Therapeutics: Research Funding; Juno Therapeutics: Research Funding; Novartis: Research Funding; Acerta Pharma: Research Funding; F. Hoffmann-La Roche Ltd.: Research Funding; National Comprehensive Care Center (NCCN): Other: Financial relationship (Chair, CLL).

*signifies non-member of ASH